Triazole-Stapled Peptides Merge Opioid and NPFF Signaling for Long-Lasting Peripheral Pain Relief
- Two-step triazole stapling built a peptide from DN-9's opioid segment, then added an NPFF pharmacophore via chimeric conjugation to form a multitarget agonist.
- The opioid-only stapled peptide acts as a μ-opioid agonist with partial δ-opioid activity; the conjugate targets μ-, κ-opioid and NPFF receptors with G-protein-biased μ signaling.
- Subcutaneous dosing of both compounds produced sustained, dose-dependent analgesia in acute and visceral pain models.
💡 Points
Stapling DN-9's opioid core with triazoles to lock the bioactive turn, then bolting on an NPFF pharmacophore via chimeric conjugation, gets you μ/κ/NPFF polypharmacology without a small-molecule fragment-merging slog — clever scaffold logic. Layering G-protein-biased μ signaling on top of peripheral restriction stacks two independent side-effect levers in one peptide, though I'd want to see the stapling's SAR tolerance before calling it tractable.